The R22X Mutation of the SDHD Gene in Hereditary Paraganglioma Abolishes the Enzymatic Activity of Complex II in the Mitochondrial Respiratory Chain and Activates the Hypoxia Pathway
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Hereditary paragangliomas are usually benign tumors of the autonomic nervous system that are composed of cells derived from the primitive neural crest. Even though three genes (SDHD, SDHC, and SDHB), which encode three protein subunits of cytochrome b of complex II in the mitochondrial respiratory chain, have been identified, the molecular mechanisms leading to tumorigenesis are unknown. We studied a family in which the father and his eldest son had bilateral neck paragangliomas, whereas the second son had a left carotid-body paraganglioma and an ectopic mediastinal pheochromocytoma. A nonsense mutation (R22X) in the SDHD gene was found in these three affected subjects. Loss of heterozygosity was observed for the maternal chromosome 11q21-q25 within the tumor but not in peripheral leukocytes. Assessment of the activity of respiratory-chain enzymes showed a complete and selective loss of complex II enzymatic activity in the inherited pheochromocytoma, that was not detected in six sporadic pheochromocytomas. In situ hybridization and immunohistochemistry experiments showed a high level of expression of markers of the angiogenic pathway. Real-time quantitative reverse transcriptase (RT)-PCR measurements confirmed that vascular endothelial growth factor and endothelial PAS domain protein 1 mRNA levels were significantly higher (three- and sixfold, respectively) than those observed in three sporadic benign pheochromocytomas. Thus, inactivation of the SDHD gene in hereditary paraganglioma is associated with a complete loss of mitochondrial complex II activity and with a high expression of angiogenic factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These clinical observations and the finding of increased expression of HIF targets in tumors with SDH mutations [9,10] have suggested the possibility that the VHL and SDH syndromes intersect at the molecular level.”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial complex II is a component of the electron transport chain, and mutations of SDHB or SDHD genes that abrogate the oxidoreductase function of complex II can cause pheochromocytomas [9,14,15].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, patients harbouring mutations in SDH have increased HIF-1α activity23,24 and circulating succinate25.”
From Succinate is an inflammatory signal that induces IL-1β through HIF-1α (2013) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, mutations in subunit SdhB, SdhC, or SdhD are linked to tumorigenesis in the form of autosome-dominant familial paragangliomas and pheochromocytomas (1, 3, 16, 19, 33).”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [19]
In the citing paper
“A relationship between SDH function and oxygen regulation has been suspected based on previous identification of increased expression of angiogenic factors in cases of SDH-mutant pheochromocytomas [9].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions
Higuchi, R., Fockler, C., Dollinger, G., & Watson, R. (1993) · Nature Biotechnology · doi:10.1038/nbt0993-1026 · Cited by 2,159 · cited 1×
“Relative quantitation of EPAS1 and VEGF gene expression was analyzed as a target-to-control expression ratio, using the standard curve method (Higuchi et al, 1993).”
MethodMitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 2×
“Mitochondria can act as O2 sensors by increasing the generation of reactive oxygen species, which are required for hypoxia-inducible factor 1 DNA–binding activity and subsequent increases in the synthesis of mRNA that encodes erythropoietin, vascular endothelial growth factor (VEGF), and glycolytic enzymes (Chandel et…”
BackgroundMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 6×
“The four exons of the SDHD gene (GenBank accession number AB 026906) were am- plified by PCR with primers and a procedure that has been described elsewhere (Baysal et al. 2000).”
BackgroundMethodInfluentialOxidative Phosphorylation at the fin de siècle
Saraste, M. (1999) · Science · doi:10.1126/science.283.5407.1488 · Cited by 1,313 · cited 2×
“Complex II or succinate-ubiquinone reductase (EC 1.3.99.1) is an important enzymatic complex crucial for both the tricarboxylic acid cycle and the aerobic respiratory chains of mitochondria (Saraste 1999).”
BackgroundInfluentialBiochemical and molecular investigations in respiratory chain deficiencies
Rustin, P., Chretien, D., Bourgeron, T., Gérard, B., Rötig, A., Saudubray, J. M., & Munnich, A. (1994) · Clinica Chimica Acta · doi:10.1016/0009-8981(94)90055-8 · Cited by 1,243 · cited 1×
“The activity of the respiratory-chain complexes was measured, as described elsewhere (Rustin et al. 1994).”
MethodSelf-citationAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 2×
“Then, several germline SDHD mutations were reported in families with paraganglioma (Badenhop et al. 2001; Milunsky et al. 2001) and in families with pheochromocytoma (Astuti et al. 2001a).”
BackgroundMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 2×
“The SDHC gene encoding the large subunit of cytochrome b in succinate-ubiquinone oxidoreductase was reported to correspond to the PGL3 gene (Niemann and Müller 2000; Niemann et al. 2001).”
BackgroundDifferential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes
Gerber, H.-P., Condorelli, F., Park, J., & Ferrara, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23659 · Cited by 794 · cited 1×
“First, VEGF-R1 mRNA, which encodes the VEGF receptor induced in hypoxic conditions (Gerber et al. 1997), was found to be more abundant than VEGF-R2 mRNA.”
BackgroundBourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730 · cited 1×
“The causative mutation was identified in the SDHA gene encoding the flavoprotein of complex II, and the enzymatic defect was partial (Bourgeron et al. 1995).”
BackgroundSelf-citationNeurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells
SCHMECHEL, D., MARANGOS, P. J., & BRIGHTMAN, M. (1978) · Nature · doi:10.1038/276834a0 · Cited by 723 · cited 1×
“This result was expected, because NSE is considered an indicator of neuroendocrine differentiation (Schmechel et al. 1978).”
Background
Research works printed but not linked: 2
- Koreth, 1999, Chromosomes, 11q and cancer: a review, J Pathol, 187, 28, 10.1002/(SICI)1096-9896(199901)187:1<28::AID-PATH166>3.0.CO;2-R · doi:10.1002/(sici)1096-9896(199901)187:1<28::aid-path166>3.0.co;2-r
- Pacheco-Ojeda, 1988, Carotid body at high altitudes, World J Surg, 12, 856
Cited by
Items 201–300 of 364
Mechanisms regulating immune surveillance of cellular stress in cancer
Seelige, R., Searles, S. C., & Bui, J. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2597-7 · Cited by 36
“The accumulation of succinate occurs in rare cancers with mutations in genes coding for succinate dehydrogenase, such as paragangliomas and pheochromocytomas [39, 65].”
BackgroundJugulotympanic paragangliomas: 75 years of evolution in understanding
Forbes, J. A., Brock, A. A., Ghiassi, M., Thompson, R. C., Haynes, D. S., & Tsai, B. S. (2012) · Neurosurgical FOCUS · doi:10.3171/2012.6.focus12138 · Cited by 29
Pęczkowska, M., Erlic, Z., Hoffmann, M. M., Furmanek, M. I., Ćwikła, J. B., Kubaszek, A., Prejbisz, A., Szutkowski, Z., Kawecki, A., Chojnowski, K., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1290 · Cited by 32
“Enzymatic studies in Caenorhabditis elegans and humans suggest that missense variants retain the ability of the mutated subunit of SDH to be incorporated into the heterotetrameric complex, whereas nonsense/splicing variants lead to the dissolution of the whole mitochondrial complex II (28, 29).”
BackgroundGenetic Testing in Pheochromocytoma‐ and Paraganglioma‐Associated Syndromes
Benn, D. E., Richardson, A. L., Marsh, D. J., & Robinson, B. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.011 · Cited by 36
Analysis of Selected Genes in Neuroendocrine Tumours: Insulinomas and Phaeochromocytomas
Hrašćan, R., Pećina‐Šlaus, N., Martić, T. N., Čolić, J. F., Gall‐Tros̆elj, K., Pavelić, K., & Karapandža, N. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01755.x · Cited by 32
Adrenal Medulla and Paraganglia
McNicol, A. M. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1069-1_12 · Cited by 34
DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas
Mannelli, M., Canu, L., Ercolino, T., Rapizzi, E., Martinelli, S., Parenti, G., Filpo, G. D., & Nesi, G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0523 · Cited by 30
Yu, W., He, X., Ni, Y., Ngeow, J. Y. Y., & Eng, C. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu425 · Cited by 32
Rapizzi, E., Ercolino, T., Canu, L., Giaché, V., Francalanci, M., Pratesi, C., Valeri, A., & Mannelli, M. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0263 · Cited by 30
“In particular, Gimenez-Roqueplo et al. (2001) reported that in a French family, a mutation in SDHD results in the lack of SDH activity, and they also found a loss of SDH activity in two patients with SDHB and SDHA mutations (Gimenez-Roqueplo et al. 2002, Burnichon et al. 2010).”
BackgroundZhu, D., Zhang, J., Hashem, J., Gao, F., & Chen, C. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02701-4 · Cited by 35
Targeting the Metabolic Paradigms in Cancer and Diabetes
Bosso, M., Haddad, D., Madhoun, A. S. A., & Al‐Mulla, F. (2024) · Biomedicines · doi:10.3390/biomedicines12010211 · Cited by 30
Yao, L., Barontini, M., Niederle, B., Jech, M., Pfragner, R., & Dahia, P. L. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2245 · Cited by 27
Molecular Genetic Alterations in Adrenal and Extra-Adrenal Pheochromocytomas and Paragangliomas
Dannenberg, H., Komminoth, P., Dinjens, W. N. M., Speel, E. M., & de Krijger, R. R. (2003) · Endocrine Pathology · doi:10.1385/ep:14:4:329 · Cited by 34
Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS
Tabebi, M., Dutta, R. K., Skoglund, C., Söderkvist, P., & Gimm, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010560 · Cited by 29
“In SDHx mutated tumors, metabolic abnormalities such as increased lactate dehydrogenase A (LDHA) expression and lactate production have been observed [11,12].”
Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours
Loughrey, P. B., Roncaroli, F., Healy, E. G., Weir, P., Madhu, B., Casey, R. T., Hunter, S. J., & Korbonits, M. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0157 · Cited by 28
Mitochondrial Deficiencies in the Predisposition to Paraganglioma
Lussey‐Lepoutre, C., Buffet, A., Gimenez‐Roqueplo, A., & Favier, J. (2017) · Metabolites · doi:10.3390/metabo7020017 · Cited by 31
“The first key allowing understanding the tumorigenesis pathways associated with TCA cycle mutations was the description, in the first French family of SDHD-related PGL, of increased angiogenesis and overexpression of the hypoxia inducible factor 2α (HIF2α) and one of its target, the vascular endothelial growth factor…”
BackgroundSelf-citationNaranjo‐Suarez, S., Carlson, B. A., Tobe, R., Yoo, M., Tsuji, P. A., Gladyshev, V. N., & Hatfield, D. L. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0121-y · Cited by 26
Dai, M., Bu, S., & Miao, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630310 · Cited by 29
Aita, Y., Ishii, K., Saito, Y., Ikeda, T., Kawakami, Y., Shimano, H., Hara, H., & Takekoshi, K. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00156.2012 · Cited by 24
Anti-inflammatory mechanisms of cannabinoids: an immunometabolic perspective
van Niekerk, G., Mabin, T., & Engelbrecht, A. (2019) · Inflammopharmacology · doi:10.1007/s10787-018-00560-7 · Cited by 27
Casas-Benito, A., Martínez-Herrero, S., & Martínez, A. (2023) · Cancers · doi:10.3390/cancers15102862 · Cited by 31
“A deficiency of SDH activity can also be explained by germline mutations in its subunits (SDHB and SDHD) that result in a collapse of the SDH catalytic activity, leading to succinate accumulation and excessive ROS generation [126].”
BackgroundThe role of mutation of metabolism-related genes in genomic hypermethylation
Waterfall, J. J., Killian, J. K., & Meltzer, P. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.003 · Cited by 24
Paddenberg, R., Tiefenbach, M., Faulhammer, P., Goldenberg, A., Gries, B., Pfeil, U., Lips, K. S., Piruat, J. I., López‐Barneo, J., SCHERMULY, R. T., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvr359 · Cited by 22
Marzola, M. C., Chondrogiannis, S., Grassetto, G., Rampin, L., Maffione, A. M., Ferretti, A., Opocher, G., Schiavi, F., Colletti, P. M., & Rubello, D. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31829aface · Cited by 23
Müller, U. (2011) · Neurogenetics · doi:10.1007/s10048-011-0280-y · Cited by 24
“As in PGLs caused by SDHD and SDHB mutations [13, 20–23], malignant and secreting tumors have also been found in PGLs caused by SDHC mutations [24].”
BackgroundHypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas
Amorim-Pires, D., Peixoto, J., & Lima, J. P. (2016) · Cytogenetic and Genome Research · doi:10.1159/000457479 · Cited by 26
Smestad, J. A., Hamidi, O., Wang, L., Holte, M. N., Khazal, F. J. A., Erber, L. N., Chen, Y., & Maher, L. J. (2017) · Oncotarget · doi:10.18632/oncotarget.23639 · Cited by 21
New Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes
Gimenez‐Roqueplo, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.012 · Cited by 25
Self-citationPediatric paraganglioma: An early manifestation of an adult disease secondary to germline mutations
Mora, J., Cascón, A., Robledo, M., & Català, A. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20680 · Cited by 21
“Gimenez and coworkers [8,9] have described the immediate consequences in the tumoral tissue of SDHD and SDHB mutations.”
BackgroundMcDonnell, C. M., Benn, D. E., Marsh, D. J., Robinson, B. G., & Zacharin, M. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02122.x · Cited by 23
Owens, K. M., Modica-Napolitano, J. S., & Singh, K. K. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_1 · Cited by 24
Paraganglioma syndrome type 1 in a patient with Carney–Stratakis syndrome
Ayala‐Ramirez, M., Callender, G. G., Kupferman, M. E., Rich, T. A., Chuang, H. H., Trent, J. C., Perrier, N. D., Goodarzi, M., & Jiménez, C. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.250 · Cited by 20
“Inactivation of its subunits B, C and D leads to insufficient mitochondrial complex II activity”
BackgroundImmunohistochemistry and Mutation Analysis of SDHx Genes in Carotid Paragangliomas
Snezhkina, A. V., Kalinin, D. V., Pavlov, V., Lukyanova, E., Golovyuk, A. L., Fedorova, M., Pudova, E. A., Savvateeva, M. V., Stepanov, O. A., Poloznikov, A. A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186950 · Cited by 21
Lussey‐Lepoutre, C., Pacák, K., Grossman, A. B., Taïeb, D., & Amar, L. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101938 · Cited by 25
Papaspyrou, K., Rossmann, H., Fottner, C., Weber, M. M., Mann, W. J., Lackner, K. J., & Helling, K. (2008) · Head & Neck · doi:10.1002/hed.20746 · Cited by 19
Zhao, Z., Rothery, R. A., & Weiner, J. H. (2006) · Biochemistry and Cell Biology · doi:10.1139/o06-188 · Cited by 18
“…Our finding that the PGL-related mutation SdhD-H71L significantly reduces the succinate–ubiquinone reductase activity of E. coli Sdh qualitatively agrees with the reported clinical observation that Sdh activity was very low in tumor tissues from patients with PGL (Gimenez-Roqueplo et al. 2001).”
BackgroundResultKonieczna, A., Szczepańska, A., Sawiuk, K., Łyżeń, R., & Węgrzyn, G. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.11.016 · Cited by 18
“An association of SDH dysfunction with activation of the hypoxia pathway has been reported [149].”
BackgroundFunctional Consequences of Succinate Dehydrogenase Mutations
Opocher, G., & Schiavi, F. (2011) · Endocrine Practice · doi:10.4158/ep11070.ra · Cited by 18
No evidence for involvement of SDHD in neuroblastoma pathogenesis
Preter, K. D., Vandesompele, J., Hoebeeck, J., Vandenbroecke, C., Smet, J., Nuyts, A., Laureys, G., Combaret, V., Roy, N. V., Roels, F., et al. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-55 · Cited by 17
“It seems that most of the individuals with PC possess SDHD mutations in the 5' portion of the gene causing complete disassembly of complex II, whereas PGL are associated with mutations in the 3' region of the gene causing partial inactivation of its catalytic activity [19-28].”
BackgroundCasting an eye on the Krebs cycle
Münnich, A. (2008) · Nature Genetics · doi:10.1038/ng1008-1148 · Cited by 20
Novel Hereditary Forms of Pheochromocytomas and Paragangliomas
Dahia, P. L. M. (2013) · Frontiers of hormone research · doi:10.1159/000345671 · Cited by 18
Filler, K., Lyon, D., McCain, N. L., Bennett, J. P., Fernández‐Martínez, J. L., deAndrés‐Galiana, E. J., Elswick, R. K., Lukkahatai, N., & Saligan, L. N. (2015) · Biological Research For Nursing · doi:10.1177/1099800415617848 · Cited by 16
“Authors have proposed that mitochondrial Complex II is implicated in the activation of the hypoxia/angiogenesis response (Gimenez-Roqueplo et al., 2001).”
BackgroundIshii, T., Yasuda, K., Miyazawa, M., Mitsushita, J., Johnson, T. E., Hartman, P. S., & Ishii, N. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.02.013 · Cited by 16
“…and colleagues studied the biological effects of a loss-of-function SDHD germline mutation (p.Arg22X) in an extra-adrenal PGL and a missense SDHB germline mutation (p.Arg46Gln) in a malignant PHEO with a somatic terminal deletion of 1p (Gimenez-Roqueplo et al., 2001; Gimenez-Roqueplo et al., 2002).”
BackgroundCancer and pulmonary hypertension: Learning lessons and real-life interplay
Pullamsetti, S. S., Nayakanti, S. R., Chelladurai, P., Mamazhakypov, A., Mansouri, S., Savai, R., & Seeger, W. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.10 · Cited by 16
Wang, Z., Chen, H., Xue, L., He, W., Shu, W., Wu, H., & Wang, Z. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101146 · Cited by 17
“Previous studies showed that HNPGL tumorigenesis is the result of mutations in genes encoding the complex II subunit of the mitochondrial respiratory chain, which is involved in the process of oxidative phosphorylation and might also function as a cellular oxygen sensor [31,32].”
BackgroundHensen, E. F., Goeman, J. J., Oosting, J., van der Meij, A. G. L., Hogendoorn, P. C. W., Cremers, C. W. R. J., Devilee, P., & Cornelisse, C. J. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-25 · Cited by 17
“HIF1α and HIF1α downstream target genes have been shown to be upregulated in SDH-linked tumors[9,38-40].”
Dekker, P. B. D., Kuipers‐Dijkshoorn, N. J., Baelde, H. J., van der Mey, A. G. L., Hogendoorn, P. C. W., & Cornelisse, C. J. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.06.013 · Cited by 15
“Because the chemosensoric chief cells of carotid bodies may have adapted particularly sensitive oxygen sensor systems, such a pseudohypoxic signal could eventually promote tumor formation through activation of hypoxia pathways and induction of angiogenesis [3-5].”
BackgroundRole of VEGF-A and Its Receptors in Sporadic and MEN2-Associated Pheochromocytoma
Ferreira, C. V., Siqueira, D. R., Romitti, M., Ceolin, L., Brasil, B. A., Meurer, L., Capp, C., & Maia, A. L. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045323 · Cited by 14
Oxidative phosphorylation inducers fight pathological angiogenesis
Bayona‐Bafaluy, M. P., Esteban, O., Ascaso, J., Montoya, J., & Ruiz‐Pesini, E. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.014 · Cited by 14
Oxidative Phosphorylation Dysfunction Modifies the Cell Secretome
Garrido-Pérez, N., Vela‐Sebastián, A., López‐Gallardo, E., Emperador, S., Iglesias, E., Meade, P., Jimenez-Mallebrera, C., Montoya, J., Bayona‐Bafaluy, M. P., & Ruiz‐Pesini, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093374 · Cited by 16
“Increased VEGF mRNA expression, and stimulation of the angiogenic pathway, were found in paraganglioma and pheochromocytoma tumors carrying mutations in nDNA-encoded CII subunits SDHB and SDHD that result in decreased CII activity [73,74].”
Background15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma
Mannelli, M., Rapizzi, E., Fucci, R., Canu, L., Ercolino, T., Luconi, M., & Young, W. F. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0215 · Cited by 15
Velasco, A., Palomar-Asenjo, V., Ga??an, L., Catasús, L., Llecha, N., Panizo, Á., Palomar-Garcia, V., Quer, M., & Matías‐Guiu, X. (2005) · Diagnostic Molecular Pathology · doi:10.1097/01.pas.0000158987.07907.7e · Cited by 16
Genetics of pheochromocytoma and paraganglioma: New developments
Pigny, P., & Cardot-Bauters, C. (2009) · Annales d Endocrinologie · doi:10.1016/j.ando.2009.11.004 · Cited by 14
Igaz, P., Wiener, Z., Szabó, P. M., Falus, A., Gaillard, R. C., Horányi, J., Rácz, K., & Tulassay, Z. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.06.011 · Cited by 13
Mori, M. P. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2015.tde-20072015-105008 · Cited by 13
Zuo, L., Chen, Z., Chen, L., Kang, J., Shi, Y., Liu, L., Zhang, S., Jia, Q., Huang, Y., & Sun, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750794 · Cited by 14
Analysis of SDHD promoter mutations in various types of melanoma
Scholz, S. L., Horn, S., Murali, R., Möller, I., Sucker, A., Sondermann, W., Stiller, M., Schilling, B., Livingstone, E., Zimmer, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4665 · Cited by 14
Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism
Tevosian, S. G., & Ghayee, H. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01991 · Cited by 12
The malignant potential of a succinate dehydrogenase subunit B germline mutation
Gómez, C. F., Menéndez, E., Pineda, J. J., de Esteban, J. P. M., Anda, E., Goñi, M. J., Bausch, B., & Neumann, H. P. H. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344107 · Cited by 11
Hypoxic Signaling Pathways in Carotid Body Tumors
Cao, K., Yuan, W., Hou, C., Wang, Z., Yu, J., & Wang, T. (2024) · Cancers · doi:10.3390/cancers16030584 · Cited by 13
“Consequently, the HIF is a pivotal pathway supporting tumor growth by facilitating angiogenesis and promoting various tumor-associated phenotypes [47–49 ,”
BackgroundGreenlee, K. J., Montooth, K. L., & Helm, B. R. (2014) · Integrative and Comparative Biology · doi:10.1093/icb/icu018 · Cited by 14
Jochmanová, I., & Lazúrová, I. (2014) · Biomedical Papers · doi:10.5507/bp.2014.021 · Cited by 10
Le réseau national COMETE sur les tumeurs de la surrénale
Plouin, P., Gimenez‐Roqueplo, A., & BERTAGNA, X. Y. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32869-9 · Cited by 16
Self-citationp53 Alterations and Their Relationship to SDHD Mutations in Parasympathetic Paragangliomas
van Nederveen, F. H., Dannenberg, H., Sleddens, H. F. B. M., de Krijger, R. R., & Dinjens, W. N. M. (2003) · Modern Pathology · doi:10.1097/01.mp.0000084111.03922.4d · Cited by 11
“A complete loss of complex II enzymatic activity, due to inactivating mutations in the SDHB, SDHC, or SDHD gene and loss of heterozygosity of the corresponding wild type allele, leads to a high expression of hypoxicangiogenic responsive genes like vascular endothelial growth factor (VEGF) and endothelial periodic acid…”
Lee, S., Needleman, L., Park, J. R., Schugar, R. C., Guo, Q., Ford, J. M., & Annes, J. P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198165 · Cited by 16
Tao, Y., Feng, L., Li, R., Shen, J., & Wang, Z.-X. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.05.022 · Cited by 9
Sesti, F. F., Feola, T., Puliani, G., Centello, R., Vito, V. D., Bagni, O., Lenzi, A., Isidori, A. M., Cantisani, V., Faggiano, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.677983 · Cited by 11
“The rationale derived from the high expression of HIF1a, HIF2a, VEGF, and VEGFR arising from HIF dysregulation and hypoxia-inducible target genes’ activation, due to germline mutations of SDHD (58).”
BackgroundAllelic loss of chromosomes 8 and 19 in MENX‐associated rat pheochromocytoma
Shyla, A., Hölzlwimmer, G., Calzada‐Wack, J., Bink, K., Tischenko, O., Guilly, M., Chevillard, S., Samson, E., Graw, J., Atkinson, M. J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24925 · Cited by 9
Arsalandeh, F., Ahmadian, S., Foolad, F., Khodagholi, F., Farimani, M. M., & Shaerzadeh, F. (2015) · International Journal of Toxicology · doi:10.1177/1091581815584165 · Cited by 9
Hansel, D. E., & Rini, B. I. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.6.895 · Cited by 12
Kim, M. S., Muratore, C., Snelling, L. K., Mandelbaum, D. E., McEachern, R., Mangray, S., Faizan, M., & Quintos, J. B. (2009) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2009.22.6.565 · Cited by 8
Pugh, C. W. (2003) · Annals of Medicine · doi:10.1080/07853890310017062 · Cited by 9
Malthièry, Y., & Savagner, F. (2006) · Annales d Endocrinologie · doi:10.1016/s0003-4266(06)72588-4 · Cited by 13
“Il est maintenant démontré que les trois gènes SDH se comportent comme des gènes suppresseurs de tumeurs [7].”
Milione, M., Pusceddu, S., Gasparini, P., Melotti, F., Maisonneuve, P., Mazzaferro, V., de Braud, F., & Pelosi, G. (2012) · Cancers · doi:10.3390/cancers4030808 · Cited by 7
Maher, E. R. (2006) · British Medical Bulletin · doi:10.1093/bmb/ldl002 · Cited by 9
Back to the Future: Molecular Biology Meets Metabolism
McKnight, S. L. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.013722 · Cited by 7
“…the enzymatic activities of fumarate hydratase (FH), succinate dehydrogenase (SDH), and isocitrate dehydrogenase (IDH) centrally drive the formation or viability of certain tumors (Gimenez-Roqueplo et al. 2001; Pollard et al. 2005; Nakamura and Kaelin 2006; Parsons et al. 2008; Kaelin 2012).”
BackgroundXu, J.-J., Xu, F., Shen, S.-J., Li, T., Zhang, Y., Shang, M., Li, Y., Liu, G., Wang, X., & Cai, S. (2017) · RSC Advances · doi:10.1039/c7ra11748e · Cited by 6
Asseburg, H., Hagl, S., & Eckert, G. P. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_23 · Cited by 6
Bronchial Paraganglioma with SDHB Deficiency
Ghigna, M., Dorfmüller, P., Crutu, A., Fadel, É., & de Montpréville, V. (2016) · Endocrine Pathology · doi:10.1007/s12022-016-9422-y · Cited by 8
“ations occurring in any of the SDH genes lead to the loss of SDH enzymatic function [10] and to the absence of SDHB expression [11].”
BackgroundKrebs cycle enzymes as tumor suppressors
Baysal, B. E. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.05.012 · Cited by 6
Carotid body paraganglioma and SDHD mutation in a Greek family.
Liapis, C. D., Bellos, J. K., Halapas, A., Lembessis, P., Koutsilieris, M., & Kostakis, A. (2005) · PubMed · Cited by 6
Angiogenic and anti-angiogenic factors in adrenal tumours.
Jurczyńska, J., Zieleniewski, W., Stepien, H., & Komorowski, J. (2006) · PubMed · Cited by 5
Oxidative Phosphorylation Disease: Diagnosis and Pathogenesis
Shoffner, J. M. (2005) · Oxidative stress and disease · doi:10.1201/9781420028843.ch4 · Cited by 6
Paragangliomes tympaniques et jugulaires
Huy, P. T. B., & Duet, M. (2003) · Encyclopédie médico-chirurgicale. Oto-rhino-laryngologie · doi:10.1016/s0246-0351(03)00075-8 · Cited by 5
Metabolism of Cell Growth and Proliferation
DeBerardinis, R. J., & Thompson, C. B. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10014-7 · Cited by 11
The spectrum of SDHD mutations in Russian patients with head and neck paraganglioma
Shulskaya, M. V., Shadrina, M. I., Bakilina, N. A., Золотова, С. В., & Slominsky, P. A. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1503181 · Cited by 5
“Despite the difficulty in establishing strict genotype/phenotype associations, our findings confirm the earlier suggestion that nonsense mutations confer a more severe phenotype compared with missense mutations in SDHD gene [26].”
ResultColorectal paragangliomas with immunohistochemical deficiency of succinate dehydrogenase subunit B
Kimura, N., Ishikawa, M., & Shigematsu, K. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0630 · Cited by 7
“Alterations occurring in any of the SDH genes lead to the loss of SDH enzymatic function [5] and to the absence of SDHB expression [6, 7].”
BackgroundGenetic Markers of Mediastinal Tumors
Taylor, M. D., & Jones, D. R. (2009) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2008.09.004 · Cited by 5
Ishii, T., Yasuda, K., Miyazawa, M., Onouchi, H., Yanase, S., & Ishii, N. (2025) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.25-62 · Cited by 5
“15) In general, it has been well known that the defect in electron transport causes electron leakage from the complexes and consequently increases ROS production (Fig.”
Molecular Imaging in Hereditary Succinate Dehydrogenase Mutation–Related Paragangliomas
Marzola, M. C., & Rubello, D. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000572 · Cited by 4
“First, chronic hypoxia in the cells can favor the gene alteration, especially in the case of SDH-D mutation.(17,18) Second, in fetal life, extraadrenal paraganglionic tissue tends to degenerate after birth via cell apoptosis related to a reduction of nerve growth factor.”
BackgroundSDHD-Related Chromaffin Tumours: Disease Localisation to Genetic Dysfunction
Srirangalingam, U., Khoo, B. C. E., Matson, M. B., Carpenter, R., Reznek, R. H., Maher, E. R., Chew, S. L., & Drake, W. M. (2010) · Hormone Research in Paediatrics · doi:10.1159/000277659 · Cited by 5
Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer
Guo, S., & Addison, C. (2026) · Current Oncology · doi:10.3390/curroncol33020129 · Cited by 5
“Succinate levels increase under stresses such as hypoxia or hyperglycemia, or via dysfunction of SDH or fumarate overproduction [183–185].”
Hereditary Syndromes Involving Pheochromocytoma and Paraganglioma
Geurts, J. L., Rich, T. A., Evans, D. B., & Wang, T. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800892-8.00016-6 · Cited by 3
Analysis of Sdhd and Mmp12 in an Affected Solar Keratosis and Control Cohort
Lintell, N. A., Maguire, D. J., Griffiths, L. R., & McCabe, M. (2007) · Springer eBooks · doi:10.1007/978-0-387-71764-7_11 · Cited by 3
Genomic Imprinting and Uniparental Disomy
Wang, J.-C. C. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1688-4_20 · Cited by 3
Persu, A., Amyere, M., Gutierrez-Roelens, I., Rustin, P., Sempoux, C. L., Lecouvet, F. E., BEERS, B. E. V., Horsmans, Y., Plaen, J.-F. D., MarcHamoir, et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328317a777 · Cited by 3
Self-citationPathologies liées aux déficits du cycle de Krebs
Bénit, P., Bortoli, S., Chrétien, D., Rak, M., & Rustin, P. (2018) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(18)30120-5 · Cited by 4
“En effet s’il est possible pour les déficits en SDH d’opposer les déficits partiels mesurés dans les cas d’encéphalopathies [6] au déficit total mesuré dans les tumeurs [19], l’activité de la fumarase est réduite à quelques pourcents aussi bien pour les cas d’encéphalopathies que Les mutations des gènes codant pour la…”
BackgroundSelf-citationOhtake, M., Tateishi, K., Murata, H., Nagashima, Y., Yamanaka, S., & Yamamoto, T. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.02.147 · Cited by 3
Management of Locally Advanced and Metastatic Pheochromocytoma and Paraganglioma
Román-Gonzaléz, A., Vásquez, P. J., Hyde, S. M., Jessop, A., & Jiménez, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-44136-8_15 · Cited by 2
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications
Trembath, H. E., Yeh, J. J., & Lopez, N. (2024) · Cancer treatment and research · doi:10.1007/978-3-031-61238-1_15 · Cited by 3
Metadata
- Authors
- Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Mourad, J.-J., Plouin, P.-F., Corvol, P., Rötig, A., & Jeunemaitre, X.
- Affiliations
- Inserm (FR)
- Hôpital Saint-Michel (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 69
- Issue
- 6
- Pages
- 1186-1197
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1235531
- OpenAlex
- W1975918337
- Cited by
- 364
- References
- 44
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 12 · 2022: 8 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 9 · 2017: 12 · 2016: 15 · 2015: 14 · 2014: 32 · 2013: 24 · 2012: 19
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4248 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- hereditary paraganglioma, succinate dehydrogenase, cytochrome b, mitochondrial respiratory chain, loss of heterozygosity, pheochromocytoma, carotid body paraganglioma, hypoxia pathway, angiogenic factors, vascular endothelial growth factor, EPAS1, tumor angiogenesis, SDHC, SDHB
- MeSH terms
- Adult, Aged, Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 11, Consanguinity, Electron Transport, Female, Humans, Immunohistochemistry, Male, Middle Aged, Mitochondria, Oxygen, Paraganglioma, Pedigree, RNA, Messenger, Succinate Dehydrogenase, Cell Hypoxia, Gene Expression, In Situ Hybridization, Germ-Line Mutation, Codon, Nonsense, Loss of Heterozygosity, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.